Emtricitabine
Emtricitabine: 2 brands, 2 generics; first approved Jul 02, 2003; generic available.
Generic available: 2 ANDA applications approved.
Brand (NDA) products
Generic (ANDA) products (2)
- EMTRICITABINEAUROBINDO PHARMA LTDANDA 0791882023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MG CAPSULE ORAL Rx AB - EMTRICITABINECIPLAANDA 0911682018
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MG CAPSULE ORAL Rx AB
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
Approvals span 2003–2023 across 4 FDA applications.
Emtricitabine: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Emtricitabine
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo